# A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

> **NCT01440088** · PHASE3 · COMPLETED · sponsor: **Threshold Pharmaceuticals** · enrollment: 640 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** TH-302 in Combination with Doxorubicin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT01440088
- **Lead sponsor:** Threshold Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-12
- **Final completion:** 2016-05
- **Target enrollment:** 640 (ACTUAL)
- **Last updated:** 2016-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01440088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01440088, "A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01440088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*